Projects per year
Organization profile
Organisation profile
This doctoral research program was established in collaboration with Academia Sinica to cultivate interdisciplinary research that focuses on tumor-related medicine. Academia Sinica is Taiwan’s leading research institute and has outstanding scientific researchers and cutting-edge equipment for advanced research. TMU also works in collaboration with its three affiliated hospitals and has access to their clinical resources.
Through these relationships, the Cancer Biology and Drug Discovery program offers students a great opportunity to build a career with excellent research support. We enroll top students from around the world, and provide a strong curriculum of interdisciplinary training as well as a learning environment where students work with many research specialists.
From basic research to translational medicine, we develop cutting-edge therapeutic strategies for cancer prevention and treatment. We work hard for cancer patients, seeking to extend their lives and improve their quality of life.
Fingerprint
Dive into the research topics where Ph.D. Program for Cancer Molecular Biology and Drug Discovery is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Chi-Long Chen
- Department of Pathology - Professor
- Graduate Institute of Clinical Medicine - Joint-Appointment Professor
- International Master/Ph.D. Program in Medicine - Joint-Appointment Professor
- Professional Master Program in Artificial Intelligence in Medicine - Joint-Appointment Professor
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery - Joint-Appointment Professor
- Taipei Medical University Hospital - Visiting Staff
- TMU Research Center of Cancer Translational Medicine - Member
- TMU Research Center of Artificial Intelligence in Medicine and Health - Member
Person: Researcher
-
Hsin-Yi Chen
- Master Program in Graduate Institute of Cancer Biology and Drug Discovery - Associate Professor
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery - Joint-Appointment Associate Professor
Person: Researcher
-
Ruei-Ming Chen
- Graduate Institute of Medical Sciences - Professor
- International Master/Ph.D. Program in Medicine - Joint-Appointment Professor
- Ph.D. Program for Cancer Molecular Biology and Drug Discovery - Joint-Appointment Professor
- TMU Research Center of Neuroscience - Member
Person: Researcher
-
跨機構合作的癌症轉譯研究計畫-建立台灣攝護腺癌治療新模式：精進診斷、提升品質和延長生命(第2年)
1/1/23 → 12/31/23
Project: A - Government Institution › c - Ministry of Health and Welfare
-
Study Roles of Interleukin-1 Receptor Antagonist (Il1rn) in Pancreatic Cancer (2/3)
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
Characterization of Tead4 as a Master Regulator of Mitochondrial Activities and a Potential Oncogene for Prostate Cancer( II )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
Research output
-
(Thyroid) Hormonal regulation of breast cancer cells
Hercbergs, A., Lin, H. Y., Mousa, S. A. & Davis, P. J., Jan 2023, In: Frontiers in Endocrinology. 13, 1109555.Research output: Contribution to journal › Short survey › peer-review
Open Access -
ASPM activates Hedgehog and Wnt signaling to promote small cell lung cancer stemness and progression
Cheng, L-H., Hsu, C-C., Tsai, H-W., Liao, W-Y., Yang, P-M., Liao, T-Y., Hsieh, H-Y., Chan, T-S. & Tsai, K. K., Jan 1 2023, In: Cancer Research.Research output: Contribution to journal › Article › peer-review
-
Association between clustering of unhealthy behaviors and depressive symptom among adolescents in Taiwan: A nationwide cross-sectional survey
Bui, C., Lin, L. Y., Lin, C. J., Chiu, Y. W. & Chiou, H. Y., 2023, In: Frontiers in Public Health. 11, 1049836.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
Huang, S. (Contributor), Liu, P. (Contributor), Kuo, C. (Contributor), Chen, C. (Contributor), Lee, W. (Contributor), Tsai, Y. (Creator) & Lin, Y. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3794620.v1, https://figshare.com/collections/The_G_h-PLC_1_signaling_axis_drives_metastatic_progression_in_triple-negative_breast_cancer/3794620/1
Dataset
-
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
Tu, H. (Contributor), Lin, Y. (Contributor), Chao, M. (Contributor), Sung, T. (Creator), Wu, Y. (Creator), Chen, Y. (Creator), Lin, M. (Contributor), Liou, J. (Creator), Pan, S. (Contributor) & Yang, C. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4350887.v1, https://springernature.figshare.com/collections/The_anticancer_effects_of_MPT0G211_a_novel_HDAC6_inhibitor_combined_with_chemotherapeutic_agents_in_human_acute_leukemia_cells/4350887/1
Dataset
-
Additional file 1: Figure S1. of DEF6 expression in ovarian carcinoma correlates with poor patient survival
Lee, Y. (Contributor), Chen, C. (Contributor), Liew, P. (Contributor), Fang, C. (Contributor), Lee, Y. (Contributor) & Chu, J. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3607517_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3607517_d1.v1
Dataset